Endocrine Abstracts

JOINT859

Objective: Central precocious puberty(CPP) is on the rise around the world. Premature puberty and acceleration of bone maturation can cause a decrease in the final adult height(FAH) by rapid bone fusion, so it is beneficial to FAH by inhibiting excessive sex hormone secretion and bone maturation through Gonadotropin-releasing hormone agonist(GnRHa) treatment. This study was conducted on a large scale compared to previous studies to see how FAH of patients with CPP treated with GnRHa was beneficial compared to the target height(TH) what factors were associated.

Methods: This study involved a total of 92 patients who were treated with GnRHa and reached FAH of total 668 male patients diagnosed with CPP at the department of pediatrics of Severance children’s hospital between January 2000 and June 2024. FAH was defined as the bone age(BA) of 16 years or older, and the yearly growth rate(YGR) was less than 1 cm/yr, the difference between FAH and TH(FAH-TH) was evaluated for growth benefits after GnRHa treatment. We compared the difference between BA and chronological age(CA) at the beginning and end of treatment. In addition, we analyzed the correlation with factors such as Tanner stage, age at start and end of treatment, treatment period, height, weight, body mass index(BMI), predicted adult height(PAH), standard deviation score(SDS), BA at beginning and end of treatment, laboratory test results (LH, FSH, peak LH, Testosterone) with FAH via univariate linear regression followed by multivariate linear regression.

Results: TH was 172. 39±3. 36cm, initial PAH was 169. 04±4. 34cm, FAH was 173. 62±6. 42cm, FAH showed a statistically significant increase of 1. 23±5. 86cmcompared to TH (P = 0. 047), and 4. 58±4. 11cmcompared to initial PAH (P < 0. 001). The difference between BA and CA was 1. 69±0. 64 years before treatment and 0. 57±1. 00 years after treatment. 1. 12±0. 91 years of delay in bone maturation at the end of treatment was significantly observed (P < 0. 001). The difference between the FAH and TH was positively associated with height and PAH before treatment (β=0. 434, 0. 359, respectively, all P < 0. 05), negatively associated with initial testosterone and peak LH (β=-0. 240, 0. 221, respectively, all P < 0. 05). The difference between the FAH and initial PAH was positively associated with height before treatment (β=0. 473, P < 0. 05), negatively associated with age, weight before treatment and peak LH (β=-0. 349, 0. 301, -0. 382, respectively, all P < 0. 05).

Conclusion: GnRHa benefits FAH and inhibits bone maturation in male CPP patients. Taller height, PAH, younger, less weight, low testosterone and peak LH level at treatment is better for FAH.